Phase II
Imugene announced a clinical trial collaboration and supply deal with Merck, while Merck said it is halting a Keytruda combination trial with AstraZeneca in prostate cancer.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.
Shares of Sanofi took a hit in premarket trading after it announced its Phase II breast cancer study assessing an experimental oral SERD failed to hit the mark.
Pfizer will cease operations within Russia and proceeds from its subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine.
This week is starting off strong with some positive clinical news from Ascendis Pharma, Can-Fite and BridgeBio.
The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here’s a look.
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
The discovery of a unique, inheritable resistance to Ebola infection has inspired the development of therapeutics that may not only be effective against Ebola but against COVID-19, as well.
Capricor Therapeutics announced less-than-stellar Q4 2021 and full-year 2021 financial results and said the company stopped efforts on its COVID-19 vaccine.
Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.
PRESS RELEASES